Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Microbiome-mediated immune modulation refers to the collective influence of the commensal microbiota on the development, function, and regulation of the host immune system. Microbial organisms in the gut and other barrier sites interact with immune cells through their metabolites, conserved structural components, and signaling pathways, shaping both innate and adaptive immune responses. This interaction helps maintain tolerance to harmless antigens, fine-tune barrier immunity, and calibrate responses to pathogens. Disruption of microbiome composition has been associated with increased risk of autoimmune, inflammatory, infectious, and even cancer-related diseases.
Modulation of cytokine production (e.g., IL-22, IL-1β); Induction of regulatory T cells (Tregs); Production of microbial metabolites (e.g., short-chain fatty acids, SCFAs) that affect immune cells; Interaction with host pattern recognition receptors (PRRs), such as Toll-like receptors (TLR5, TLR9) and Nod-like receptors
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Microbiome-mediated immune modulation.